XNASSTSS
Market cap3mUSD
Dec 24, Last price
1.95USD
1D
5.41%
1Q
1,203.48%
IPO
12.72%
Name
Sharps Technology Inc
Chart & Performance
Profile
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | |||||
Cost of revenue | 11,018 | 9,393 | 4,526 | ||
Unusual Expense (Income) | |||||
NOPBT | (11,018) | (9,393) | (4,526) | ||
NOPBT Margin | |||||
Operating Taxes | (30) | (5,420) | 167 | ||
Tax Rate | |||||
NOPAT | (10,988) | (3,974) | (4,693) | ||
Net income | (9,842) -1,361.93% | 780 -116.14% | (4,831) 105.83% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 8,030 | 14,267 | 3,378 | ||
BB yield | -148.14% | -145.56% | |||
Debt | |||||
Debt current | 700 | ||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (3,013) | (4,171) | (812) | ||
Cash flow | |||||
Cash from operating activities | (8,507) | (6,433) | (3,148) | ||
CAPEX | (698) | (752) | (2,269) | ||
Cash from investing activities | (698) | (3,118) | (2,344) | ||
Cash from financing activities | 8,030 | 12,235 | 5,180 | ||
FCF | (10,469) | (8,009) | (7,683) | ||
Balance | |||||
Cash | 3,013 | 4,171 | 1,479 | ||
Long term investments | 32 | ||||
Excess cash | 3,013 | 4,171 | 1,512 | ||
Stockholders' equity | (24,556) | (15,092) | (10,667) | ||
Invested Capital | 32,490 | 24,733 | 14,503 | ||
ROIC | |||||
ROCE | |||||
EV | |||||
Common stock shares outstanding | 13,033 | 8,100 | 9,172 | ||
Price | 0.42 -65.63% | 1.21 | |||
Market cap | 5,420 -44.70% | 9,801 | |||
EV | 2,407 | 5,631 | |||
EBITDA | (10,136) | (8,739) | (4,498) | ||
EV/EBITDA | |||||
Interest | 138 | 1,320 | 168 | ||
Interest/NOPBT |